168 related articles for article (PubMed ID: 38363020)
1. Phosphorylation of PBK at Thr9 by CDK5 correlates with invasion of prolactinomas.
Fang Q; Liu C; Nie D; Guo J; Xie W; Zhang Y
CNS Neurosci Ther; 2024 Feb; 30(2):e14629. PubMed ID: 38363020
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylation of kinase insert domain receptor by cyclin-dependent kinase 5 at serine 229 is associated with invasive behavior and poor prognosis in prolactin pituitary adenomas.
Xie W; Liu C; Wu D; Li Z; Li C; Zhang Y
Oncotarget; 2016 Aug; 7(32):50883-50894. PubMed ID: 27438154
[TBL] [Abstract][Full Text] [Related]
3. PBK/TOPK Inhibitor Suppresses the Progression of Prolactinomas.
Zhu K; Cheng X; Wang S; Zhang H; Zhang Y; Wang X; Chen Y; Wu J
Front Endocrinol (Lausanne); 2021; 12():706909. PubMed ID: 35126305
[TBL] [Abstract][Full Text] [Related]
4. MiR-137's Tumor Suppression on Prolactinomas by Targeting MITF and Modulating Wnt Signaling Pathway.
Lei C; Jing G; Jichao W; Xiaohui L; Fang Q; Hua G; Yazhou M; Zhang Y
J Clin Endocrinol Metab; 2019 Dec; 104(12):6391-6402. PubMed ID: 31162548
[TBL] [Abstract][Full Text] [Related]
5. [Expression of galectin-3 in invasive prolactinomas].
Wang H; Wang MD; Ma WB; Yang D; Shi YF; Kong YG; Li SF; Li ZH; Wang RZ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Jun; 27(3):380-1. PubMed ID: 16038281
[TBL] [Abstract][Full Text] [Related]
6. Role of E-cadherin, alpha-, beta-, and gamma-catenins, and p120 (cell adhesion molecules) in prolactinoma behavior.
Qian ZR; Li CC; Yamasaki H; Mizusawa N; Yoshimoto K; Yamada S; Tashiro T; Horiguchi H; Wakatsuki S; Hirokawa M; Sano T
Mod Pathol; 2002 Dec; 15(12):1357-65. PubMed ID: 12481018
[TBL] [Abstract][Full Text] [Related]
7. Thrombospondin-1 and transforming growth factor-β1 levels in prolactinoma and their clinical significance.
Jiang M; Mou CZ; Han T; Wang M; Yang W
J Int Med Res; 2012; 40(4):1284-94. PubMed ID: 22971480
[TBL] [Abstract][Full Text] [Related]
8. The expression of AIB1 correlates with cellular proliferation in human prolactinomas.
Carretero J; Blanco EJ; Carretero M; Carretero-Hernández M; García-Barrado MJ; Iglesias-Osma MC; Burks DJ; Font de Mora J
Ann Anat; 2013 May; 195(3):253-9. PubMed ID: 23433587
[TBL] [Abstract][Full Text] [Related]
9. P21
Dong W; Li J; Liu Q; Liu C; Li C; Song G; Zhu H; Gao H; Zhang Y
J Neurooncol; 2018 Feb; 136(3):485-494. PubMed ID: 29230669
[TBL] [Abstract][Full Text] [Related]
10. β-Catenin is reduced in membranes of human prolactinoma cells and it is inhibited by temozolomide in prolactin secreting tumor models.
Demarchi G; Valla S; Perrone S; Chimento A; Bonadeo N; Vitale DL; Spinelli FM; Cervio A; Sevlever G; Alaniz L; Berner S; Cristina C
Tumour Biol; 2022; 44(1):85-105. PubMed ID: 35811548
[TBL] [Abstract][Full Text] [Related]
11. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.
Cristina C; Díaz-Torga GS; Goya RG; Kakar SS; Perez-Millán MI; Passos VQ; Giannella-Neto D; Bronstein MD; Becu-Villalobos D
Mol Cancer; 2007 Jan; 6():4. PubMed ID: 17222350
[TBL] [Abstract][Full Text] [Related]
12. Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands.
Vlotides G; Siegel E; Donangelo I; Gutman S; Ren SG; Melmed S
Cancer Res; 2008 Aug; 68(15):6377-86. PubMed ID: 18676863
[TBL] [Abstract][Full Text] [Related]
13. Curcumin (diferuloylmethane) inhibits cell proliferation, induces apoptosis, and decreases hormone levels and secretion in pituitary tumor cells.
Miller M; Chen S; Woodliff J; Kansra S
Endocrinology; 2008 Aug; 149(8):4158-67. PubMed ID: 18450960
[TBL] [Abstract][Full Text] [Related]
14. What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics.
Gürlek A; Karavitaki N; Ansorge O; Wass JA
Eur J Endocrinol; 2007 Feb; 156(2):143-53. PubMed ID: 17287403
[TBL] [Abstract][Full Text] [Related]
15. Functional characterization of DLK1/MEG3 locus on chromosome 14q32.2 reveals the differentiation of pituitary neuroendocrine tumors.
Chen Y; Gao H; Liu Q; Xie W; Li B; Cheng S; Guo J; Fang Q; Zhu H; Wang Z; Wang J; Li C; Zhang Y
Aging (Albany NY); 2020 Dec; 13(1):1422-1439. PubMed ID: 33472171
[TBL] [Abstract][Full Text] [Related]
16. Cdk5-mediated phosphorylation regulates phosphatidylinositol 4-phosphate 5-kinase type I γ 90 activity and cell invasion.
Li L; Kołodziej T; Jafari N; Chen J; Zhu H; Rajfur Z; Huang C
FASEB J; 2019 Jan; 33(1):631-642. PubMed ID: 30040488
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor α/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas.
Xiao Z; Yang X; Zhang K; Liu Z; Shao Z; Song C; Wang X; Li Z
Int J Med Sci; 2020; 17(18):3174-3189. PubMed ID: 33173437
[TBL] [Abstract][Full Text] [Related]
18. Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk.
Paez-Pereda M; Giacomini D; Refojo D; Nagashima AC; Hopfner U; Grubler Y; Chervin A; Goldberg V; Goya R; Hentges ST; Low MJ; Holsboer F; Stalla GK; Arzt E
Proc Natl Acad Sci U S A; 2003 Feb; 100(3):1034-9. PubMed ID: 12552124
[TBL] [Abstract][Full Text] [Related]
19. Cyclin-dependent kinase 5 modulates STAT3 and androgen receptor activation through phosphorylation of Ser⁷²⁷ on STAT3 in prostate cancer cells.
Hsu FN; Chen MC; Lin KC; Peng YT; Li PC; Lin E; Chiang MC; Hsieh JT; Lin H
Am J Physiol Endocrinol Metab; 2013 Oct; 305(8):E975-86. PubMed ID: 23941877
[TBL] [Abstract][Full Text] [Related]
20. ALK7 expression in prolactinoma is associated with reduced prolactin and increased proliferation.
Principe M; Chanal M; Karam V; Wierinckx A; Mikaélian I; Gadet R; Auger C; Raverot V; Jouanneau E; Vasiljevic A; Hennino A; Raverot G; Bertolino P
Endocr Relat Cancer; 2018 Sep; 25(9):795-806. PubMed ID: 30012586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
